Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

88.07USD
22 Jul 2019
Change (% chg)

$0.58 (+0.66%)
Prev Close
$87.49
Open
$87.36
Day's High
$88.71
Day's Low
$87.27
Volume
6,566,074
Avg. Vol
5,421,357
52-wk High
$88.71
52-wk Low
$62.87

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $154,348.20
Shares Outstanding(Mil.): 1,764.18
Dividend: 0.32
Yield (%): 1.46

Financials

  ABT Industry Sector
P/E (TTM): 53.21 32.80 34.52
EPS (TTM): 1.64 -- --
ROI: -- 14.10 12.69
ROE: -- 65.83 17.17

Abbott hits record high as diabetes device fuels profit beat

Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.

Jul 17 2019

UPDATE 3-Abbott hits record high as diabetes device fuels profit beat

* Shares rise 4% (Adds details on FreeStyle Libre; Updates shares)

Jul 17 2019

US STOCKS-Wall St flat as railroads slide after CSX signals trade impact

* Dow flat, S&P off 0.05%, Nasdaq 0.06% higher (Updates to open)

Jul 17 2019

Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

Jul 16 2019

FOCUS- Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO, July 16 Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

Jul 16 2019

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

Jun 10 2019

CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

June 8 Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

Jun 10 2019

Abbott Labs quarterly beat overshadowed by unchanged forecast

Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

Apr 17 2019

UPDATE 2-Abbott Labs quarterly beat overshadowed by unchanged forecast

April 17 Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

Apr 17 2019

Abbott Lab's first-quarter sales beat expectations

April 17 Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.

Apr 17 2019

Earnings vs. Estimates